Selected article for: "effective treatment and international license"
Author: changzheng wang; Chengbin Li
Title: Preliminary study to identify severe from moderate cases of COVID-19 using NLR&RDW-SD combination parameter
  • Document date: 2020_4_14
    • ID: jecsj3xw_44
    Snippet: Currently, SARS-CoV-2 virus has begun to spread globally, but there is no clinically effective drug for COVID-19. Before SARS-CoV-2 vaccine can pass clinical trials and be widely and safely applied [35] , it is inevitable that more patients will develop into severe or even critical patients. To establish an effective treatment strategy for severe and critical patients depends on early diagnosis . CC-BY-NC-ND 4.0 International license It is made a.....
    Document: Currently, SARS-CoV-2 virus has begun to spread globally, but there is no clinically effective drug for COVID-19. Before SARS-CoV-2 vaccine can pass clinical trials and be widely and safely applied [35] , it is inevitable that more patients will develop into severe or even critical patients. To establish an effective treatment strategy for severe and critical patients depends on early diagnosis . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

    Search related documents:
    Co phrase search for related documents
    • cc NC ND International license and early diagnosis: 1, 2, 3, 4
    • cc NC ND International license and globally spread: 1
    • cc NC ND International license and International license: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cc NC ND International license and SARS vaccine: 1
    • cc NC ND International license and SARS virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • cc NC ND International license and treatment strategy: 1, 2
    • clinical trial and critical severe patient: 1
    • clinical trial and early diagnosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • clinical trial and globally spread: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • clinical trial and International license: 1, 2, 3
    • clinical trial and SARS vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • clinical trial and SARS virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • clinical trial and treatment strategy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • critical severe patient and early diagnosis: 1, 2, 3
    • critical severe patient and globally spread: 1
    • critical severe patient and International license: 1
    • critical severe patient and SARS virus: 1, 2
    • early diagnosis and SARS virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • early diagnosis and treatment strategy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10